Claims for Patent: 10,071,170
✉ Email this page to a colleague
Summary for Patent: 10,071,170
Title: | Antibody-drug conjugate having improved stability and use thereof |
Abstract: | The present invention relates to an antibody-drug conjugate comprising a drug conjugated to an antibody, a preparation method thereof and the use thereof. |
Inventor(s): | Kim; Young Min (Gyeonggi-do, KR), Ko; Min Ji (Daejeon, KR), Kim; Jae Yong (Seoul, KR), Kim; Ju Hee (Daejeon, KR), Moon; Kyung Duk (Daejeon, KR), Song; Dae Hae (Daejeon, KR), Eom; Jae Hyun (Sejong, KR), Jung; Jin Won (Dajeon, KR) |
Assignee: | ABLBIO (Seoul, KR) |
Application Number: | 14/898,126 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,071,170 |
Patent Claims: | 1. An antibody-drug conjugate comprising a cytotoxic drug conjugated to the N-terminal amino acid residue of the heavy chain or light chain of an antibody, wherein the
cytotoxic drug is site-specifically conjugated to the N-terminal .alpha.-amine group of native first amino acid of the heavy chain or light chain of the antibody, and the cytotoxic drug is conjugated to the antibody by a linker having a reactive aldehyde
group, and the conjugate is produced through reductive alkylation by the aldehyde group.
2. The antibody-drug conjugate of claim 1, wherein the antibody includes full-length antibodies or antibody fragments containing antigen binding domains. 3. The antibody-drug conjugate of claim 2, wherein the antibody is selected from the group consisting of IgG, scFv, Fv, Fab, Fab', and F(ab')2. 4. The antibody-drug conjugate of claim 1, wherein the cytotoxic drug is selected from the group consisting of microtubule structure formation inhibitors, meiosis inhibitors, RNA polymerase inhibitors, topoisomerase inhibitors, DNA intercalators, DNA alkylators, ribosome inhibitors, radioisotopes, and toxins. 5. The antibody-drug conjugate of claim 4, wherein the cytotoxic drug is selected from the group consisting of maytansinoid, auristatin, dolastatin, tubulysin, calicheamicin, pyrrolobenzodiazepines, doxorubicin, duocamycin, carboplatin(paraplatin), cisplatin, cyclophosphamide, ifosfamide, nidran, nitrogen mustard(mechlorethamine HCL), bleomycin, mitomycin C, cytarabine, fluorouracil, gemcitabine, trimetrexate, methotrexate, etoposide, vinblastine, vinorelbine, alimta, altretamine, procarbazine, paclitaxel, docetaxel, topotecan, irinotecan, trichothecene, CC1065, alpha-amanitin, other enediyne antibiotics, exotoxin, and plant toxin. 6. The antibody-drug conjugate of claim 5, wherein the auristatin is monomethyl auristatin E or monomethyl auristatin F. 7. The antibody-drug conjugate of claim 1, wherein the antibody binds specifically to a cancer cell surface antigen. 8. The antibody-drug conjugate of claim 7, wherein the cancer cell surface antigen is selected from the group consisting of CD19, CD20, CD30, CD33, CD37, CD22, CD56, CD70, CD74, CD138, Muc-16, mesothelin, HER2, HER3, GPNMB (glycoprotein NMB), IGF-1R, BCMA (B cell maturation antigen), PSMA (prostate-specific membrane antigen), EpCAM (Epithelial cell adhesion molecule), and EGFR (epidermal growth factor receptor). 9. The antibody-drug conjugate of claim 1, wherein the antibody is selected from the group consisting of an anti-HER2 antibody, an anti-CD30 antibody, an anti-CD56 antibody, and an anti-GPNMB (glycoprotein NMB) antibody. 10. The antibody-drug conjugate of claim 9, wherein the antibody is selected from the group consisting of Trastuzumab, Lorvotuzumab, Brentuximab, and Glembatumumab. 11. A pharmaceutical composition for treating cancer, which comprises the antibody-drug conjugate of claim 1. |
Details for Patent 10,071,170
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2033-06-24 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2033-06-24 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2033-06-24 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.